Biota's flu drug fails mid-stage study

August 1, 2014 11:51 AM

15 0

Two doses of the drug, laninamivir octanoate, were being tested against a placebo in 639 patients to treat influenza A and B infections, the company said.

Patients given a 40 milligram (mg) or 80 mg dose did not achieve a statistically significant reduction, compared with the placebo, in the median time to alleviate influenza symptoms - the main goal of the trial, Biota said.

Also read: Behemoths Have Dominated the Market Before, but Tech Is Different

Read more

To category page